Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 16  |  Issue : 69  |  Page : 235-241

Fucoxanthin attenuates the lipopolysaccharide-induced sepsis and acute lung injury through the inactivation of nuclear factor-kappa B signaling pathway


1 Department of Critical Care Medicine, Yunnan Cancer Hospital, Kunming City, Yunnan Province, 650118, China
2 Department of Emergency, First Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan Province, 650032, China

Correspondence Address:
Mingyao Xiao
Department of Critical Care Medicine, Yunnan Cancer Hospital, Kunming City, Yunnan Province, 650118
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_487_19

Rights and Permissions

Objectives: The acute lung injury was a very severe health consequence and it was allied with the highest morbidity as well as mortality rate among the peoples. The acute lung injury can be induced through the various direct or indirect causative factors such as serious septic conditions, inflammation of the lung tissues, swelling of the lungs, injury of inhalation, pulmonary vasculitis, pancreatitis, and severe burnings which can lead to the unrestrained inflammation. Materials and Methods: The sepsis was a major clinical syndrome that can cause by severe infection or injury and it was distinguished by the response to the entire body inflammation. The current research work aimed to assess the curative properties of fucoxanthin against the lipopolysaccharides (LPS)-induced acute lung injury in the experimental animal model. Results: The fucoxanthin treatment followed by the LPS administration was exhibited the marked reduction in the wet-to-dry ratio of the lungs, reduced level of infiltration of inflammatory cells in BALF, reduced the enzymatic action of myeloperoxidase in the lungs, reduced the interleukin-6 (IL-6), IL-1 β, and tumor necrosis factor-alpha levels, possessed the notable suppression and downregulation in the expression of immunoreactivity of inflammatory markers like NF-κB p65 and decreased the oozing of mucus and the inflammatory cellular infiltration in lung histopathology which is stimulated by the LPS administration. Conclusion: The fucoxanthin was effectively attenuated the LPS-stimulated acute lung injury in an animal model. Hence, it can be concluded that the fucoxanthin had potent therapeutic properties against the LPS-stimulated acute lung injury.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed76    
    Printed2    
    Emailed0    
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal